Key facts: Alamar-GSK Study 60,000 Samples; Target Up; White Retires

What happened

Alamar Biosciences will work with GSK to analyze more than 60,000 serum samples using its NULISA protein panels, connecting results with clinical data to study disease markers and treatment responses. The company’s average 12-month price target rose to $35.80 from $35.40, and President Tod White plans to retire at the end of 2026.

Confirmed

Global impact / market context

The GSK study could give Alamar evidence about how its protein panels perform on a large sample set, potentially supporting future customer interest or research work. The price-target increase reflects higher analyst expectations, while White’s planned departure creates a leadership transition to track.

Analyst inference

The supplied summary reports four Buy ratings, one Hold, no Sell, and an average target implying 18% upside from Alamar’s Nov. 3 close. These are analyst opinions, not company results; the summary gives no study revenue, contract value, or financial forecast.

Confirmed

What to watch

1. Watch for updates on the GSK collaboration, including whether the sample analysis produces findings on disease markers or treatment responses and whether either company describes commercial terms. Analyst inference
2. Check whether Alamar reports new customer demand, revenue, or costs linked to the study; the supplied summary does not state that the collaboration has a disclosed financial value. Analyst inference
3. Track the announced leadership timeline: Tod White plans to retire at the end of 2026 and advise Alamar through June 2027. Confirmed

Evidence

• Original source link unavailable